Teresa M. Macarulla
Expertise in
7
conditions

Teresa M. Macarulla

Barcelona, CT, ES 
Expertise in
7
conditions
Barcelona, CT, ES 

Overview

Teresa Macarulla practices in Barcelona, Spain. Ms. Macarulla is highly rated in 7 conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, and PIK3CA-Related Overgrowth Spectrum.

Her clinical research consists of co-authoring 179 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Barcelona, CT, Spain
Other Locations
Pi, CT 08036, Spain
Bellaterra, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase Ib/IIa Study to Evaluate Safety and Efficacy of Treatment With the Hedgehog Inhibitor NLM-001 and Chemotherapy (Gemcitabine and Nab-Paclitaxel) Plus Zalifrelimab as First Line Treatment in Patients With Advanced Pancreatic Cancer
Phase Ib/IIa Study to Evaluate Safety and Efficacy of Treatment With the Hedgehog Inhibitor NLM-001 and Chemotherapy (Gemcitabine and Nab-Paclitaxel) Plus Zalifrelimab as First Line Treatment in Patients With Advanced Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab paclitaxel, NLM-001, Zalifrelimab
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: BL-8040, Pembrolizumab, Chemotherapy of Onivyde
Study Phase: Phase 2
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Enrollment Status: Terminated
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRINOX
A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRINOX
Enrollment Status: Unknown
Publish Date: August 02, 2022
Intervention Type: Drug
Study Drug: NALRINOX combination
Study Phase: Phase 2
A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Drug, Genetic
Study Phase: Phase 1
View 5 Less Clinical Trials

179 Total Publications

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
Journal: The New England journal of medicine
Published: March 25, 2026

Frequently Asked Questions about Teresa M. Macarulla

Is Teresa M. Macarulla a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Teresa M. Macarulla is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Teresa M. Macarulla participate in research or clinical trials?

Yes. Teresa M. Macarulla has published 179 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Teresa M. Macarulla's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Macarulla's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile